שווי הפעילות העסקית: alnylam.com (ALNY)

Alnylam Pharmaceuticals (ALNY) leads the field of pathogenic gene silencing via RNA interference, developing therapies for rare pathologies. The stock price history reflects the impact of successes in amyloidosis drugs and the cardiology pipeline, with the indicator standing at 22962.13. Growth is constrained by biochemical supply chain challenges and geopolitical restrictions. Meanwhile, production capacities are steadily upgraded, ensuring the uninterrupted release of innovative medicines.

Enterprise Value combines market capitalization and net debt, determining the actual cost of a full business buyout inclusive of all liabilities. By analyzing the total capital level of Alnylam Pharmaceuticals (ALNY) on GURU.Markets, an investor assesses the financial stability of Alnylam Pharmaceuticals, whose capital-intensive developments in RNA interference require a precise balance between borrowed funds and the value of genetic innovations.